Seladelpar and Fostemsavir: Interaction Details
AI-assisted, pharmacist-reviewed · Source data updated Aug 8, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Fostemsavir
Seladelpar
No brand names on record
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
What happens
Increased seladelpar exposure
Interaction Deep Dive
Coadministration of seladelpar and OATP1B1/OATP1B3 and BCRP inhibitors may increase seladelpar exposure. In a drug interaction study in healthy subjects, coadministration of 10 mg seladelpar dose with 600 mg cycloSPORINE (OATP1B1, OATP1B3 and BCRP inhibitor) increased seladelpar AUC and Cmax by 2.1-fold and by 2.9-fold, respectively. If coadministered, closely monitor patients for adverse effects1.
Why it happens (mechanism)
Inhibition of OATP1B1-mediated efflux transport of seladelpar; inhibition of OATP1B3-mediated efflux transport of seladelpar; inhibition of BCRP-mediated efflux transport of seladelpar
Literature reports
1 report — tap to read
a) In a drug interaction study in healthy subjects, coadministration of 10 mg seladelpar dose with 600 mg cycloSPORINE (OATP1B1, OATP1B3 and BCRP inhibitor) increased seladelpar AUC and Cmax by 2.1-fold and by 2.9-fold, respectively 1.
Common questions
Can I take Seladelpar and Fostemsavir together?
Increased seladelpar exposure Always confirm with your pharmacist or prescriber before making any change.
How serious is the Seladelpar and Fostemsavir interaction?
It is rated moderate. Can be significant — usually manageable with monitoring.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How strong is the evidence for this interaction?
The evidence is graded "probable". Good supporting evidence, though not definitively proven.
Questions for your pharmacist
- Does my dose of Seladelpar or Fostemsavir need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there anything you'd monitor while I'm on both?
References (1)
- Product Information: LIVDELZI® oral capsules, seladelpar oral capsules. Gilead Sciences, Inc. (Per Manufacturer), Foster City, CA, 2026. DailyMed
Keep reading about Fostemsavir
Keep reading about Seladelpar
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist